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a  b  s  t  r  a  c  t
Objective: This study investigated the co-existence of Leishmania chagasi infection and
childhood leukemia in patients naïve to treatment; this has serious clinical and
epidemiological implications.
Methods: The seroprevalence of L. chagasi antibodies prior to any treatment was investigated
in  children with clinical features of acute leukemia. Serological tests were performed in 470
samples drawn from under 14-year-old children from different regions of Brazil with clinical
suspicion of acute leukemia. Acute leukemia subtypes were characterized by immunophe-
notyping using ﬂow cytometry. Morphological analyses of bone marrow aspirates were
systematically performed to visualize blast cells and/or the formation of L. chagasi amastig-
otes.  Data analysis used a standard univariate procedure and the Pearson’s chi-square test.
Results: The plasma of 437 children (93%) displayed antibodies against L. chagasi by indi-
rect  immunoﬂuorescence assay and enzyme-linked immunosorbent assay tests. Of the 437
patients diagnosed from 2002 to 2006, 254 had acute lymphoblastic leukemia, 92 had acute
myeloid leukemia, and 91 did not have acute leukemia. The seroprevalence of L. chagasi
antibodies according to the indirect immunoﬂuorescence assay test (22.5%) was similar in
children with or without acute leukemia (p-value = 0.76). The co-existence of visceral leish-
manasis and acute leukemia was conﬁrmed in 24 children. The overall survival of these
children was poor with a high death rate during the ﬁrst year of leukemia treatment.
Conclusion: In the differential diagnosis of childhood leukemia, visceral leishmanasis should
be  considered as a potential concurrent disease in regions where L. chagasi is endemic.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Instituto Nacional de Câncer (INCA), Centro d
Rio  de Janeiro, RJ, Brazil.
E-mail address: mpombo@inca.gov.br (M.S. Pombo-de-Oliveira).
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ntroduction
cute leukemia (AL) is the most common childhood malig-
ancy. It is recognized as a disease with heterogeneous
iological characteristics. Great progress has been made
oward a cure and understanding the pathogenesis of AL.1,2
n international survey of data that compared the relative
requencies of the different AL subtypes has demonstrated
onsistent frequencies among groups stratiﬁed according to
ge, gender, ethnicity, and social conditions.3,4 To clarify
he etiology of childhood leukemia, epidemiological stud-
es have attempted to gain some understanding about the
ifferent rates of acute lymphoblastic leukemia (ALL) and
cute myeloid leukemia (AML) in association with genet-
cs, infections, and other environmental factors.5 A recent
opulation-based study of childhood leukemia demonstrated
hat substantial regional differences exist in the incidence of
L in Brazil, which warrants further studies.4 These differ-
nces may be related to the underreporting of AL cases in some
ess-developed areas. In this context, visceral leishmaniasis
VL) or Kala-zar, a tropical disease caused by the intracellu-
ar protozoan parasite, Leishmania infantum (syn. L. chagasi),
hould be considered clinically as a co-morbid disease that
an complicate the diagnosis of AL. The signs and symptoms
f VL are very similar to those of some childhood types of AL.
ffected children present splenomegaly, anemia, neutropenia,
hrombocytopenia, and/or increased abnormal lymphocyte
ounts. Coagulation abnormalities have also been found in
atients, often associated with disseminated intravascular
oagulopathy.6 Additionally, atypical cells and unusual blasts
ay be observed in bone marrow aspirates of patients with
L.7,8 Thus, it is important to include VL in the differential
iagnosis of AL in endemic areas.
In Brazil, VL frequently occurs in remote locations and
ndemic areas, and for the general pediatrician, AL is not
he ﬁrst disease to be investigated. Furthermore, VL treat-
ent is often performed on the basis of clinical suspicion,
ecause it is associated with high mortality in the absence
f treatment.9 The ﬁnal diagnosis of AL is hampered by the
omplexity of clinical diagnoses, for instance, infections can
timulate the hypothalamus–pituitary–adrenal axis, leading
o increased plasma cortisol levels that are sufﬁciently high to
liminate clonal leukemic cells,10 thereby delaying decisions.
n essence, AL and VL are serious diseases that require a rapid,
roper diagnosis and adequate treatment to reduce childhood
ortality. The present study investigated a series of samples
rom patients suspected of childhood leukemia at diagnosis,
or the presence of L. chagasi antibodies and evaluated how
he relationship between these two severe diseases can affect
hildren.
ethods
ubjectserum samples from 785 children were selected for this
tudy. The study population was enrolled throughout a multi-
isciplinary project that had been ongoing in the Pediatric
ematology-Oncology Program of the Research Center at 1 4;3  6(5):356–362 357
the Instituto Nacional de Câncer (INCA), Rio de Janeiro,
Brazil. Bone marrow (BM) aspirations and peripheral blood
(PB) samples were sent for immunophenotyping-genotyping
for a study on acute childhood leukemia during the period
of 2001–2007. Complete epidemiological data have been
described in detail elsewhere.11 Biological samples (BM and
PB) were ﬁrst evaluated to determine the morphological char-
acteristics of lymphoid and myeloid blast cells. Then, an
algorithm of immuno-molecular testing was performed: (i)
morphological characteristics of lymphoid and myeloid cells
according to standard criteria, (ii) immunophenotyping of BM
aspirates; (iii) DNA index (only in ALL) and (iv) identiﬁcation
of abnormal fusion genes according to leukemia subtypes.12
The panel of monoclonal antibodies (MoAb) recommended
by the European Group for the Immunological Characteriza-
tion of Leukemias was applied to isolated mononuclear cells
and analyzed by ﬂow cytometry.13 Brieﬂy, the combination
of ﬂuorochrome-labeled MoAbs was used in triplet and/or
quadruple staining experiments, using ﬂuorescein isothio-
cyanate (FITC), phycoerythrin (PE) and PE-cyanine 5 (PECy5)
and/or APC ﬂuorochrome conjugates in each tube. Cell sam-
ples were analyzed by ﬂow cytometry using a FACSCalibur
device (Becton, Dickinson and Company, CA, USA) with the
Cell-Quest and Paint-a-Gate computer programs.
1. Intracytoplasmatic – CD79b and/or CD22FITC/CD3PE/
CD45PECy5 or APC; TdTFITC/aMPOPE/CD33/CD13 PECy5/
CD45APC as initial screening;
2. Membrane surface according to screening results – if B-cell
markers (CD79/CD22/TdT+) were positive, then CD10FITC/
CD19PE/CD45PECy5, CD34FITC/CD38PE/CD45PECy5,
CD58FITC/CD10PE/CD19PECy5/CD45APC,
SmIgFITC/CD20PE/CD19 PECy5 and CD4FITC/CD8PE/CD3
PECy5/CD45APC were performed. If T-cell markers
(cCD3/TdT+) were positive, then CD7FITC/CD33/13PE/
CD45PECy5, CD34FITC/CD1aPE/CD45PECy5 and
CD4FITC/CD8PE/CD3 PECy5/CD45APC were performed.
Finally, a panel for anti-myeloid antigen cells was tested
when myeloid morphology and/or intracytoplasmatic




Cell surface antigens were considered positive when 20% or
more  cells showed ﬂuorescence intensity greater than the neg-
ative control in the gate for CD45low cells, while the cutoff for
the cytoplasmic antigen aMPO was 10% in the gate for CD45low
cells. Cases with unusual positive markers were tested
twice.
AL types were classiﬁed as B cell precursor ALL (Bcp-ALL),
pro-B-cell, common B, and pre-B ALL; B-ALL; T-ALL, and AML
accordingly.11,13 Subsequently, RNA was processed for c-DNA;
MLL-AF4, TEL-AML1,  E2A-PBX1 and BCR-ABL1 were performed
in the Bcp-ALL samples, whereas, the SIL-TAL1 fusion and
HOX11L2 were performed in T-ALLs as has been described
14,15elsewhere.
Patients with diagnoses that excluded ALL or AML  and
other malignant diseases were designated to the ‘Non-
leukemic Group’.
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Exclusion criteria for the serological analysis were sam-
ples from children that presented with malignancies other
than AL, children who had been submitted to treatment
for malignancies or those with well-documented VL treat-
ment.
Serologic  assays  and  diagnosis  of  visceral  leishmaniasis
Serum and plasma samples were screened for reactions
to different antigens related to VL using an indirect
immunoﬂuorescence antibody assay (IFA) and the enzyme-
linked immunosorbent assay (ELISA) (both kits from Bio-
Manguinhos/Oswaldo Cruz Foundation, Rio de Janeiro, Brazil).
IFA is indicated for the diagnosis of VL by the Health Ministry
in Brazil.16 ELISA screening tests were performed accord-
ing to de Assis et al.9 Brieﬂy, soluble antigens of L. chagasi
and the recombinant K39 were immobilized to solid-phase
wells for 16–18 h at room temperature. Unbound antigens
were removed, and the wells were blocked. A peroxidase-
conjugated anti-human IgG secondary antibody was used
to detect antibody binding. The reaction was blocked using
50 L 8 M sulfuric acid, and was analyzed with a BioRad-
Benchmark Microplate Reader equipped with a 490 nm ﬁlter.
Specimens were considered positive when titers were at or
above 1:80 and negative when titers were less than 1:40; results
that fell between these levels were considered indetermi-
nate.
BM smears were evaluated by optic microscopy to search
for the presence of amastigotes within histiocytes and neu-
trophils.
Statistical  analysis
Patient characteristics (age, skin color, Brazilian region of resi-
dence, and AL sub-type) and serological results were analyzed
with the standard univariate procedure. The Pearson chi-
square test was used to compare the frequency of serological
positivity between different groups (e.g., the AL Group vs. the
Non-leukemia Group, different Brazilian regions, different age
strata); the Fisher exact test was used when a cell count of
less than ﬁve was expected. p-values less than 0.05 were con-
sidered statistically signiﬁcant. All statistical analyses were
performed with the IBM SPSS Statistics package, version 18.0
(Chicago, Il, USA).
Due to the lack of consensus between ELISA and IFA results,
the percentage of agreement and Cohen’s Kappa statistic
were calculated with a standard formula. The sensitivity,
speciﬁcity, positive predictive value (PPV), and negative pre-
dictive value (NPV) were used to evaluate the performance of
the ELISA test. Sensitivity was calculated with the formula:
TP/(TP + FN); where TP represents the true positive results
based on IFA results (recommended as reference), and FN rep-
resents the false negative results. Speciﬁcity was calculated
with the formula: TN/(TN + FP); where TN represents the true
negative and FP represents the false positive results. The con-
cordance between the IFA and ELISA tests was calculated.
Quality control criteria regarding concordance values were:
≤40%, fair; 40.1–79.9%, moderate; 80–89.9%, substantial; and
≥90%, almost perfect.8,11 2 0 1 4;3  6(5):356–362
Ethical  considerations
The Ethics and Scientiﬁc Committees of the Instituto Nacional
de Cancer – INCA, Rio de Janeiro, approved the study
(CEP#070/07: O papel das infecc¸ões e da resposta imune desregu-
lada na etiologia das leucemias da infância analisado através da
assinatura genética). Written, informed consent was obtained
from mothers or relatives responsible for the enrolled children
prior to AL treatment.
Results
For the present study, records of demographic characteristics,
disease signs and symptoms noted at the time of sample col-
lection, diagnostic procedures, and clinical follow-ups were
examined. Data from 752 out of 785 (95.8%) children who  had
undergone serological tests are shown in Table 1. The patients
were identiﬁed from pediatric cancer centers located in dif-
ferent Brazilian states, including Rio de Janeiro, São Paulo
(Southeastern region); Bahia, Paraíba, (Northeastern region);
Mato Grosso, Mato Grosso do Sul, Federal District (Central-
western region); and Paraná, Rio Grande do Sul (Southern
region). Thirty-three cases were excluded because children
had undergone previous chemotherapy and/or VL treatment,
and/or they lacked biological samples for double-checking the
serological tests. For 115 patients, morphology, immunophe-
notyping, and clinical follow-ups ruled out the diagnosis of
AL, and they were designated the Non-leukemic Group. There
were 637 patients with ALL; of these, 391 (61.5%) had Bcp-ALL,
84 (13.2%) had T–ALL, and 153 (24.1%) had AML. All children
were under 14 years old at diagnosis, with a range of four
months to 12.3 years. There was a predominance of children
between two to ﬁve years of age (40.3%), and from the North-
eastern region (61.6%).
To examine whether a possible bias was introduced in
selecting study patients, the clinical characteristics of patients
with and without AL in this study were compared (Table 2). No
statistical difference was found between groups in respect to
gender, age, skin color/ethnicity (not shown), or AL subtypes.
However, the variability found might be due to missing values
from the number of valid observations in the input data set of
the Non-leukemia Group.
All samples were ﬁrst tested with ELISA to determine the
presence of L. chagasi. Fifty-four had positive results; of these,
39 samples were conﬁrmed positive by IFA. Similarly, the 381
samples that were negative in the ELISA test were also tested
by IFA. Of these, the IFA identiﬁed 56 positive and 325 negative
cases. IFA was determined as the gold standard for seropreva-
lence. The observed agreement between ELISA and IFA was
83.1% and the observed unweighted Kappa statistic was 0.42
(95% conﬁdence interval [95% CI]; 31.2–52.6). The percentage
of agreement was considered ‘moderate’. Regarding the per-
formance of the ELISA, its sensitivity was found to be 41.1%
(95% CI: 36.1–51.6%), speciﬁcity was 94.8% (95% CI: 91.8–96.9%),
the positive predictive value was 68.4% (95% CI: 54.8–80.1%)
and negative predictive value was 85.3% (95% CI: 81.3–88.7%).
Therefore, cases diagnosed as IFA seropositive have a 41.1%
chance of being ELISA positive too (sensitivity); likewise, ELISA
positive have a 68.4% chance of being IFA positive (speciﬁcity).
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≤1 66 (8.8) 51 (8.0) 38 (8.0) 13 (8.0) 15 (13.0) 0.001
2–5 303 (40.3) 246 (38.6) 197 (41.5) 49 (30.2) 57 (49.6)
6–10 208 (27.7) 188 (29.5) 141 (29.7) 47 (29.0) 20 (17.4)
>11 175 (23.3) 152 (23.9) 99 (20.8) 53 (32.7) 23 (20.0)
Gender
Male 455 (60.5) 391 (61.4) 293 (61.7) 98 (60.5) 64 (55.7) 0.49
Female 297 (39.5) 246 (38.6) 182 (38.3) 64 (39.5) 51 (44.3)
Geographical regions
Northeast 463 (61.6) 380 (59.7) 275 (57.9) 105 (64.8) 83 (72.2) 0.59
Southeast/South 196 (26.1) 175 (27.5) 135 (28.4) 40 (24.7) 21 (18.3)
Central-west 93 (12.4) 82 (12.9) 65 (13.7) 17 (10.5) 11 (9.6)
Seroprevalence of L. chagasia
Overall 95 (21.7) 75 (21.5) 65 (25.6) 10 (10.5) 20 (22.5) 0.01
Total 752 (100) 637 (100) 475 (100) 162 (100) 115 (100)

































aa Indirect immunoﬂuorescence antibody test positive to Leishmania c
Based on the IFA results, the prevalence of L. chagasi anti-
odies was 21.7% of the entire cohort, 25.6% among ALL cases,
nd 10.5% among AML  cases; the seroprevalence in the Non-
eukemic Group was 22.5% (p-value = 0.01). The seroprevalence
as also analyzed according to Brazilian region (Table 3).
he prevalence was lowest in the southeastern and central-
estern regions. The prevalence ranged from 7.1% for AML
ases and 16.7% for non-leukemia cases in the southeastern
egion to 12.9% for AML  cases and 30.0% in ALL cases in the
ortheastern regions (p-value = 0.01).
Based on symptoms, clinical signs, and antibody pos-
tivity in both serological tests, the diagnosis of VL was
onﬁrmed in 20 children (without leukemia) and additionally,
4 children (19 ALL and 5 AML) had high L. chagasi antibody
iters by ELISA and positive IFA. Most of these 24 children
resented symptoms characterized by fever, anorexia, and
eight loss. Clinical examinations showed that the majority
f patients demonstrated pallor, splenomegaly, hepatomegaly,
nd lymphomegaly. Laboratory analyses showed that all of
hese patients demonstrated anemia and thrombocytopenia.
eukopenia was found in four cases, normal leukocyte lev-
ls were found in seven cases, and elevated white blood cell
ounts were found in 15 cases (data not shown). Amastig-
tes were found in ﬁve cases (four patients with AML and one
atient with Bcp-ALL); BM hypocellularity and an increased
umber of histiocytes were observed in ﬁve patients with ALL.
he co-existence of AL and VL was strongly correlated in these
ases. Overall survival of these children was poor; ten patients
ied before the ﬁrst year of treatment. A one-year follow up
howed persistent BM eosinophilia in one child.
iscussionhis unique study tested the co-existence of VL and childhood
L in patients, prior to any chemotherapeutic treatment. The
ssociation between VL and chronic leukemia in adulthoodi.
has been reported previously. In addition, anecdotal studies
have described cases of VL that occurred during the treat-
ment of childhood ALL.7,17–20 The co-existence of these two
diseases is clinically relevant, because they have serious clin-
ical and epidemiological consequences in childhood. Among
these are: (i) VL can mimic  AL (or vice versa) in young children;
(ii) L. chagasi can infect children that have ALL or AML  (as a co-
morbidity); and (iii) L. chagasi may play a role as a risk factor
in the hematological malignancy process.
To appraise these points, it is ﬁrst mandatory to discuss the
wide prevalence of the two entities. The incidences of both
diseases in the population depend on their recognition and
notiﬁcation. As pointed out by de Assis et al.,9 the clinical diag-
nosis of VL may be inaccurate, because its clinical presentation
shares some common features with critical diseases. The lab-
oratory diagnosis of L. chagasi infection remains complex and,
until recently, there was no consensual gold standard; thus,
VL treatment is frequently based on clinical suspicion.9,21
Despite this, about 3500 cases of VL are registered in Brazil
every year. Generally, the disease is associated with poor liv-
ing conditions. Nevertheless, a shift has been observed toward
an increase of cases in urban areas; thus, L. chagasi infections
have become an important medical problem in different areas
of Brazil.22,23 Brazilian national initiatives have given rise to
referral centers that provide oncological care for childhood
leukemia in different regions. This has created particularly
favorable conditions for exploring the natural history of child-
hood leukemia in Brazil.11,24 The present study indicated
that the majority of oncological clinics located in areas with
endemic L. chagasi infections continue to have difﬁculties in
making a ﬁrm diagnosis of VL. The clinical manifestations of
VL, such as fever, anemia, splenomegaly, lymphadenopathy,
thrombocytopenia, and myelodysplasia features can lead to
a misdiagnosis of AL, due to overlapping clinical criteria. In
the present series of cases, 91 children were evaluated for AL
and excluded as non-leukemic patients. These patients had






















Table 2 – Clinical, laboratorial characterization of the cohort of acute leukemia cases and non-leukemic children in Brazil.
Clinical and laboratorial variables Total (n = 752) ALL (n = 475) AML (n = 162) Non-leukemiaa (n = 115)
WBC (×109/L) − median (interquartile range) 17,400 (5000–64,100) 20,000 (5760–71,150) 24,000 (7300–86,500) 5520 (2900–16,000)
Hemoglobin (g/dL) − median (interquartile range) 7.5 (5.5–9.3) 7.4 (5.4–9.3) 7.4 (6.1–8.9) 8.1 (5.5–10.3)
Platelets (×109/L) − median (interquartile range) 50,000 (24,750–105,500) 49,500 (26,250–99,750) 42,000 (20,000–88,000) 92,000 (27,000–238,25)
AL subtypesb – n (%)
Bcp-ALL 391 (61.5) 391 (61.5) –  –
T-ALL 84 (13.2) 84  (13.2) –  –
AML – – 153 (24.1) –
Initial ﬁndingsb – n (%)
Hepatomegaly 453 (72.6) 275 (76.0) 117 (75.0) 61 (57.5)
Splenomegaly 356 (57.0) 238 (65.4) 77 (49.7) 41 (38.7)
Enlarged lymph nodes 300  (54.2) 213 (65.9) 46 (33.6) 41  (43.6)
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; WBC: white blood cells count.
a Designated as Non-leukemic Group due to absence of laboratorial criteria for acute leukemia.
b Due to missing values, the number of observations used for an individual table analysis can differ from the number of valid observations in the input data set; the concomitant visceral leishmaniasis
patients are included.
Table 3 – Serological analyses for detecting Leishmania chagasi according to major geographical regions in Brazil.




(n  = 62)
Non-leukemia
(n  = 63)
ALL
(n  = 98)
AML (n = 28) Non-leukemia
(n  = 18)
ALL
(n  = 16)
AML
(n  = 5)
Non-leukemia
(n  =  8)
ELISA – n (%) 24 (17.1) 11 (17.7) 12 (19.0) 6 (6.1) 1 (3.6) 1 (5.6) 0 1 (20.0) 1 (12.5)
IFA – n (%) 42 (30.0) 8 (12.9) 16 (25.4) 19 (19.4) 2 (7.1) 3 (16.7) 4(25.0) 0 1 (12.5)
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ublic Healthcare System guidelines, they were treated for
L.16 Some of the most striking features of this study is (1)
he extremely high prevalence of exposure to L. chagasi at a
oung age (as low as one-year old); (2) the lack of values of an
LISA screening test that showed a sensitivity of only 41.1%; (3)
he presentation of AL in many  cases as hypoplastic marrow
hereby misleading the diagnosis.
Our results could not elucidate the question of whether
he development of VL would be facilitated in children with
L due to the immunocompromised status of these patients.
owever, we  did ﬁnd that 24 children with ALL or AML had
oncomitantly high serological L. chagasi titers. Immunodeﬁ-
iency is often found in patients with leukemia; this condition
ncreases vulnerability to opportunistic diseases. Our results
id not distinguish whether L. chagasi infections occurred
efore or after the onset of leukemia. However, the detec-
ion of low levels of L. chagasi antibodies in patients with ALL
uggested that a signiﬁcant fraction of children with AL in
razil had had contact with L. chagasi. It has been shown that
ntibody titers decline sharply over time, with or without VL
reatment.25 Therefore, it is possible that some children in our
tudy had been exposed to leishmania infections.
A very speculative topic is whether an L. chagasi infection
ight be a risk factor for the malignancy process. One poten-
ial role of either a leishmania infection or VL treatment might
e mutational hits that would facilitate the development of AL.
his notion is biologically plausible and should be explored
urther with the appropriate study design and other reﬁned
ethods. The L. chagasi infection promotes lymphoid differ-
ntiation and proliferation, which disturbs the immunological
ramework, or the balance between Th1 and Th2 functional
ells.26 It has been postulated that perturbations of the
h1/Th2 balance may contribute to an increasing incidence
f serious childhood diseases, such as asthma, diabetes, and
L.27,28 The present study demonstrates that children affected
y VL harbored 25–35% of immature cells, characterized by
mmature B-cell precursor markers and dysplastic BM mor-
hology features. This could mean that L. chagasi infections
ight stimulate the immune system with increased B-cell
recursors and induce susceptibility to somatic mutations.
Another important issue is the impact of VL treatment
ith highly active, toxic drugs in young children. Sodium sti-
ogluconate (SAG), pentamidine isethionate, paramomycin,
itamaquine, imidazole derivatives, alkylphosphocholine
nalogs, amphotericin B, and lipid-associated amphotericin
 are the drug choices for the treatment of VL. Most of these
rugs can potently damage DNA. The precise mechanism of
ction of some of these drugs is not fully known however, SAGs
ave been shown to inhibit glycolytic enzymes and fatty acid
xidation in leishmania amastigotes.29 It is reasonable to pos-
ulate that ﬁrst, the L. chagasi infection greatly stimulates the
mmune system by increasing the production of B-cell precur-
ors, and then, the addition of DNA-damaging drugs (to treat
he L. chagasi infection) would hit genes related to the patho-
enesis of AL. These hypotheses could be tested in prospective
pidemiological studies that included long-term follow-ups of
hildren affected by L. chagasi infections.This study had some limitations that should be considered
hen interpreting the results. First, the relatively small num-
er of subjects included may not have been representative of 1 4;3  6(5):356–362 361
the populations in the central-western, southern, and north-
ern regions of Brazil. A convenience sample was used, but it
may have introduced a potential selection bias, which would
limit the generalizability of the results. The gold standard for
diagnosing VL is parasitological identiﬁcation; however, in this
study, the prevalence of L. chagasi was calculated based on the
IFA test. This approach may have reduced the accuracy of the
diagnoses.
Conclusions
In summary, our ﬁndings suggest that VL is a prevalent dis-
ease in children from endemic areas, and it is important to
include VL in the differential diagnosis of ALL and AML. There-
fore, we strongly recommend that, in areas endemic for VL,
the algorithm of diagnostic tests to identify AL should include
serological tests for L. chagasi. Furthermore, we recommend
applying the predictive models suggested by de Assis et al.
Finally, VL can occur as a concomitant disease that could lead
to poor outcomes in treating childhood leukemias. This study
shows that the prevalence of concurrent L. chagasi and AL is
not negligible in Brazil. We also show that both diseases can
be detected before administering treatment. These ﬁndings
should provide a basis for developing safer means of treating
these diseases in the future.
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